Drug Profile
Aceclofenac/eperisone controlled-release - Navipharm
Alternative Names: Aceclofenac/eperisone SR; Aceclofenac/eperisone-controlled-release; Eperisone controlled-release/aceclofenac; Eperisone SR/aceclofenac; NVP-1203; NVP-1203-RLatest Information Update: 14 Jun 2021
Price :
$50
*
At a glance
- Originator Navipharm
- Class Analgesics; Esters; Muscle relaxants; Neuroprotectants; Nonsteroidal anti-inflammatories; Phenylacetates; Piperidines; Propiophenones; Small molecules
- Mechanism of Action Calcium channel antagonists; Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Back pain
Most Recent Events
- 31 May 2021 Navipharm completes a phase III trial in Back pain in South Korea (NCT04082975)
- 28 Nov 2019 Phase-III clinical trials in Back pain in South Korea (PO) (NCT04082975)
- 11 Sep 2019 Navipharm Corporation plans a phase III trial in Back pain (NVP1203P3; NCT04082975)